Soligenix Announces Results From Phase 2a Proof Of Concept Study Evaluating SGX945 In Treatment Of Behçet's Disease Published In Rheumatology (Oxford)

• Study results support advancing SGX945 in this difficult-to-treat orphan disease
• Results suggest potential durability of response for maintenance therapy

PRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results from its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease have been published in Rheumatology (Oxford), in an article entitled "Results from a Pilot Study of Dusquetide for the Treatment of Aphthous Ulcers Associated with Behçet Syndrome".